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More than 20 years have passed since the beneﬁt of early reperfusion therapy in the set-
ting of ST-segment elevation acute myocardial infarction (STEMI) was ﬁrst demonstrated
[1]. During the past two decades the relationship between the duration of acute coro-
nary occlusion and both functional recovery and survival has also been widely accepted
[2], leading to an everyday battle to reduce the duration of coronary occlusion. Multiple
strategies have been developed:
• to reduce door-to-needle time for thrombolysis (i.e., prehospital thrombolysis in France)
and door-to-balloon time for primary percutaneous coronary interventions (PCIs) (i.e.,
prehospital triage towards the catheterization laboratory in France), to speed up the
initiation of thrombolysis or PCI;
• to develop urban primary PCI networks as well as rescue PCI networks in remote areas;
• to avoid coronary reocclusion by the use of coronary stents and intense antiplatelet
regimens;
• to prevent distal embolization by the use of ﬁlters or thrombus-extracting devices;Infarctus aigu du
myocarde ;
Fibrinolyse ;
Antithrombotiques
• to implement optimal secondary prevention.
These strategies, which have been implemented in many other countries, had one major
objective: to allow effective and universal reperfusion in almost all patients within the
golden 1 to 6 hours after onset of symptoms.
∗ Corresponding author.
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While the beneﬁt of primary PCI over thrombolysis was
rst reported in 1995 [3], it took more than 10 years for this
mprovement to emerge in European and American guide-
ines, when experts were sure that they could recommend
technique of reperfusion that was widely available; pri-
ary PCI became the ﬁrst-line reperfusion strategy within
2 hours after symptom onset in all cases, with the exception
f patients presenting to a non-PCI hospital within 3 hours
fter symptom onset and who would have a door-to-needle
ime less than 30minutes and a door-to-balloon time greater
han 90minutes [4].
In this issue of Archives of Cardiovascular Diseases, Dr
uliard and colleagues report their observations over a 20-
ear period of the management and outcomes of patients
ith STEMI presenting within 6 hours of symptom onset to
tertiary Parisian University Hospital. This smart group of
nterventional cardiologists and emergency physicians has
lways been at the cutting edge of knowledge and experi-
nce in acute myocardial reperfusion, and has sometimes
ven driven progress in this ﬁeld. Similar to other studies
5—7], the authors report a survival beneﬁt over time in the
ow-to-intermediate risk population, with a temporal trend
owards higher rates of reperfusion therapy, while rates of
ardiogenic shock remain unchanged. Of note, there was an
ncrease in the use of primary PCI and glycoprotein IIb/IIIa
nhibitors and a parallel decrease in the use of thrombolysis.
evertheless, several unique aspects distinguish the present
ork from other studies.
First, during the latest period of the study, and com-
ared with data from Global Registry of Acute Coronary
vents (GRACE) [7], patients were younger (median age 58
s 65 years) and rates of reperfusion therapy and primary
CI were higher (95.8% vs 71% and 69.9% vs 52%, respec-
ively) as was the use of glycoprotein IIb/IIIa inhibitors
87% vs 39%). Door-to-balloon (40minutes) and pain-to-
hrombolysis (144minutes) times were much lower than has
een reported. In-hospital mortality rates are neverthe-
ess comparable between the two registries (5.4% vs 4.6%).
here is an obvious leverage effect on mortality by the 5%
f patients presenting in cardiogenic shock (61% mortality
ate), while only 2.4% of patients without cardiogenic shock
95% of the study population) died during the hospital stay.
Second, when looking at the most recent periods of dif-
erent registries, cardiogenic shock at admission was twice
s frequent in the present study compared with the GRACE
7] and National Registry of Myocardial Infarction (NRMI)
egistries [5] (5% vs 1.9—2.5%), whereas the rate of cardio-
enic shock developing during hospitalization was more than
wo-fold lower despite the fact that patients were included
ithin 12 hours of symptom onset in GRACE and NRMI versus
hours in the present study. Such ﬁndings suggest that the
opulation included in the present study was at higher risk
t admission, while one may speculate that early in-hospital
anagement may have avoided the evolution towards car-
iogenic shock in a signiﬁcant subset of patients.
The authors also report a non-signiﬁcant 15% absolute
eduction in the mortality rate between 1988—1996 and
ore recently in patients with cardiogenic shock. The study
s likely to be underpowered to show a signiﬁcant differ-
nce in this subgroup of patients but the ﬁnding is still
oncordant with those of NRMI [5] and the very recently
ublished Acute Myocardial Infarction in Switzerland Reg-
[F. Beygui, G. Montalescot
stry [8], which showed a signiﬁcant temporal trend towards
decrease in mortality rates from cardiogenic shock after
TEMI. Despite such a decrease, the mortality rate remains
xtremely high in this subgroup of patients. The manage-
ent of cardiogenic shock is heterogeneous and depends on
he facilities available — surgical or not— in the centres.
hether the recent development of assistance devices such
s extracorporeal membrane oxygenation and the Tandem-
eart or Impella devices can improve the outcome of such
atients remains to be assessed.
Third, the mortality rates are not only higher in patients
n cardiogenic shock but also among those with prehospital
ardiac arrest (24% mortality rate) and surprisingly among
hose transferred from another hospital ward (19% mortal-
ty rate). Although extracardiac comorbidities and delayed
iagnosis are proposed as potential explanations for this
nding, the role of discontinuation of antiplatelet therapy
n patients with coronary artery disease, hospitalized for
on-cardiac interventions may be considered [9].
In the present study, Dr Juliard and colleagues report one
f the highest rates of reperfusion therapy and successful
eperfusion therapy (TIMI 3 ﬂow rates) as well as one of the
owest in-hospital mortality rates in STEMI patients without
ardiogenic shock presenting within the ﬁrst 6 hours. These
uperb results illustrate the excellence of both the PCI pro-
ramme and the network with key prehospital initiators of
atient management —mobile intensive care units— leading
o continuous improvement in quality of care.
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